Der-Avakian, Andre
D’Souza, Manoranjan S.
Potter, David N.
Chartoff, Elena H.
Carlezon, William A. Jr
Pizzagalli, Diego A.
Markou, Athina
Funding for this research was provided by:
National Institute of Mental Health (MH0958092)
Article History
Received: 26 November 2016
Accepted: 24 February 2017
First Online: 9 March 2017
Compliance with Ethical Standards
:
: Over the past 3 years, Dr. Pizzagalli received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Pfizer, and Posit Science, for activities unrelated to the current research. Dr. Markou received contract research support from Bristol-Myers Squibb Co., and honoraria/consulting fees from Abbott GmbH and Company, AstraZeneca, and Pfizer during the past 2 years for projects unrelated to the present research. Dr. Markou also had a patent on the use of metabotropic glutamate compounds for the treatment of nicotine dependence that is unrelated to the present research. Dr. Carlezon discloses that he is an inventor on several patents that claim the use of selective kappa opioid ligands to treat psychiatric illness (Assignee: McLean Hospital) and during the past 2 years, has received compensation as a consultant for Cerecor. No other authors report any conflicts of interest.
: This work was supported by National Institutes of Health grants R21MH078979 (DAP) and R01MH063266 (WAC). Dr. Pizzagalli was further supported by R01MH0958092 and R37MH068376. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.